Sugi Predict

Sugi Predict / Compounds / SCHEMBL1093009

SCHEMBL1093009

SCHEMBL1093009

CC(=O)c1ccc2c(c1)OC(C)(C)C2

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ KDM4E B2RXH2 3/20 0.45
▸ KMT2A Q03164 1/20 0.44
▸ HSD17B1 P14061 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ OGA O60502 1/20 0.39
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ AKR1B1 P15121 1/20 0.37
▸ RXRA P19793 1/20 0.37
▸ TRPM8 Q7Z2W7 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ APEX1 P27695 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ PGR P06401 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL103150 0.87 MAPT (0.47) MAPTNPC1RAB9AKDM4EKMT2A
SCHEMBL8940100 0.87 RXRA (0.49) MAPTKDM4EALDH1A1CA1CA2
SCHEMBL31085132 0.84 MAPT (0.45) MAPTNPC1RAB9AKDM4EKMT2A
SCHEMBL30780909 0.80 CYP1A2 (0.53) MAPTNPC1RAB9AKDM4EKMT2A
SCHEMBL31085058 0.80 ALDH1A1 (0.66) MAPTNPC1RAB9AKDM4EALDH1A1
SCHEMBL13481991 0.76 MAPT (0.66) MAPTNPC1KDM4EKMT2AALDH1A1
SCHEMBL28344554 0.76 CA2 (0.51) MAPTKDM4EKMT2AALDH1A1CA2
SCHEMBL1191065 0.75 KDM4E (0.55) MAPTNPC1RAB9AKDM4EKMT2A
SCHEMBL30134256 0.75 KDM4E (0.55) MAPTNPC1RAB9AKDM4EKMT2A
SCHEMBL282032 0.75 ALDH1A1 (0.60) MAPTKDM4EKMT2AALDH1A1OGA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125378-A2 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2026-05-07 — — US disclosed
EP-4658650-A1 HETEROCYCLIC COMPOUNDS Beone Medicines I GmbH (CH) 2025-12-10 — — EP disclosed
US-20250353846-A1 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2025-11-20 — — US disclosed
US-20250115604-A1 SULFOXIMINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2025-04-10 — — US disclosed
US-12157734-B2 Sulfoximine glycosidase inhibitors ASCENEURON SA (CH) 2024-12-03 — — US disclosed
WO-2024160277-A1 HETEROCYCLIC COMPOUNDS BEIGENE, LTD. (KY) 2024-08-08 — — WO disclosed
CN-110770226-B Sulfoximine glycosidase inhibitors 阿森纽荣股份公司 2023-11-10 — — CN disclosed
EP-3672958-B1 ANNULATED GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2023-08-02 — — EP disclosed
US-20220177470-A1 SULFOXIMINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2022-06-09 — — US disclosed
US-20220177470-A1 SULFOXIMINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2022-06-09 — — US disclosed
US-11261183-B2 Sulfoximine glycosidase inhibitors ASCENEURON SA (CH) 2022-03-01 — — US disclosed
US-10995090-B2 Substituted dihydrobenzofuran glycosidase inhibitors ASCENEURON SA (CH) 2021-05-04 — — US disclosed
US-10995090-B2 Substituted dihydrobenzofuran glycosidase inhibitors ASCENEURON SA (CH) 2021-05-04 — — US disclosed
US-20200289516-A1 ANNULATED GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2020-09-17 — — US disclosed
CN-110770226-A Sulfoximine glycosidase inhibitors 阿森纽荣股份公司 2020-02-07 — — CN disclosed
WO-2018153508-A2 SULFOXIMINE GLYCOSIDASE INHIBITORS Asceneuron S.A. (CH) 2018-08-30 — — WO disclosed
WO-2018153507-A1 SUBSTITUTED DIHYDROBENZOFURAN GLYCOSIDASE INHIBITORS Asceneuron S.A. (CH) 2018-08-30 — — WO disclosed
US-8153634-B2 Carbinol derivatives having cyclic linker KOWA COMPANY, LTD. (JP) 2012-04-10 — — US disclosed
EP-2281817-A1 SUBSTITUTED CARBINOL COMPOUND HAVING CYCLIC LINKER Kowa Company, Ltd. (JP) 2011-02-09 — — EP disclosed
US-20100048610-A1 CARBINOL DERIVATIVES HAVING CYCLIC LINKER KOWA COMPANY, LTD. (JP) 2010-02-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12157734-B2 Sulfoximine glycosidase inhibitors ENGASE, BACE1, GAA MAPT 42/4885NPC1 2614/4885RAB9A 1707/4885
US-20200289516-A1 ANNULATED GLYCOSIDASE INHIBITORS GAA, GBA3, ENGASE MAPT 26/4885NPC1 760/4885RAB9A 1683/4885
US-20260125378-A2 Heterocyclic Compounds NFATC1, CD4, MALT1 MAPT 3357/4885NPC1 978/4885RAB9A 1314/4885
US-20220177470-A1 SULFOXIMINE GLYCOSIDASE INHIBITORS ENGASE, BACE1, GAA MAPT 42/4885NPC1 2614/4885RAB9A 1707/4885
US-20250115604-A1 SULFOXIMINE GLYCOSIDASE INHIBITORS ENGASE, BACE1, GAA MAPT 38/4885NPC1 2286/4885RAB9A 1641/4885
US-11261183-B2 Sulfoximine glycosidase inhibitors ENGASE, BACE1, GAA MAPT 42/4885NPC1 2614/4885RAB9A 1707/4885
US-20250353846-A1 Heterocyclic Compounds NFATC1, CD4, ACIN1 MAPT 3912/4885NPC1 1729/4885RAB9A 957/4885
US-20100048610-A1 CARBINOL DERIVATIVES HAVING CYCLIC LINKER NR1H2, NR1H3, LDLR MAPT 1455/4885NPC1 151/4885RAB9A 4527/4885
US-10995090-B2 Substituted dihydrobenzofuran glycosidase inhibitors GAA, ENGASE, BACE1 MAPT 22/4885NPC1 678/4885RAB9A 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.